TikTok, Kimberley Nix
TikToker who documented journey with metastatic sarcoma dies at 31, released final video saying 'I've passed away'
TikToker Kimberley Nix, who documented her three year journey with metastatic sarcoma, has died at the age of 31.
TikToker Kimberley Nix Dead at 31 from Metastatic Sarcoma, Leaves Final Video for Followers: 'I've Passed Away'
The 31-year-old from Calgary, Alberta, first gained attention in 2021 after she began documenting her cancer journey on Instagram and TikTok. At the time of her diagnosis, Dr. Nix was 28 years old and in her third and final year of her internal medicine core residency. She is survived by her husband, Michael MacIsaac.
Who Was Kimberley Nix? Everything To Know About TikToker As She Passes Away At 31 After Battle With Metastatic Sarcoma
Kimberley Nix, a beloved influencer with a large following, lost her battle with Metastatic Sarcoma at 31. She shared her journey on tiktok.
TikTok star Kimberley Nix announces her own death in heartbreaking farewell video
"Hello followers, if you're seeing this message I have passed away peacefully," the late social media star announced in the heartbreaking clip that was released posthumously.
TikToker Kimberley Nix Dead at 31 from Metastatic Sarcoma, Leaves Final Video for Followers: 'I've Passed Away'
Kimberley Nix was a 28-year-old medical resident when she was diagnosed with metastatic sarcoma Jordan Greene is Society and Culture writer-reporter at PEOPLE. She has been working at PEOPLE since ...
Popular TikToker Dr. Kimberley Nix loses to cancer at 31, leaves final video for followers
On Wednesday, popular TikToker Dr. Kimberley Nix passed away, three years after being diagnosed with metastatic sarcoma. She was 31. The young content creator found a wide audience on social media after sharing her cancer journey on TikTok and Instagram in 2021.
31-year-old TikTok star, Kimberley Nix announces her own death from Metastatic Sarcoma
TikToker Dr Kimberley Knix has sadly passed away from metastatic sarcoma on Wednesday, May 8 - and announced her own death on the platform. The 31-year-old from Calgary, Alberta gained over 147,000 followers on TikTok where she documented her cancer journey after she received her diagnosis three years ago when she was 28.
TikTok star Kimberley Nix dies aged 31 and confirms news herself in final video
TikTok star Dr. Kimberley Nix has died aged 31 three years after being diagnosed with metastatic sarcoma. The 31-year-old doctor rose to fame on social media in 2021 as she, then 28 and in her final three of her internal medicine core residency,
Kimberley Nix, beloved TikToker dies at 31 after announcing her own death in video; ‘'I've Passed Away'
Dr. Kimberley Nix, a beloved influencer with a large following, lost her battle with Metastatic Sarcoma at 31. She shared her journey on tiktok.
Everyday Health on MSN3d
What Is De Novo Metastatic Breast Cancer? Symptoms, Causes, Diagnosis, Treatment, and Prevention
Metastatic breast cancer is cancer that has spread from the breast to other parts of the body, such as the bones, liver, ...
Medscape1d
AUA 2024: Anticipating Developments in Metastatic Prostate Cancer Research
AUA 2024 offers valuable learning opportunities, including forums on advanced prostate cancer and instructional courses on ...
hospitalnews10d
A new hope for men with metastatic prostate cancer
Explore a groundbreaking new therapy for metastatic prostate cancer. Learn about the promising results of the Actinium-225 ...
Cancer Therapy Advisor3d
HRR Testing Underused in Metastatic Castration-Resistant Prostate Cancer
HRR testing is underused in patients with metastatic castration-resistant prostate cancer, a large study suggests.
The American Journal of Managed Care10d
Destiny-Breast06 Results Offer New Hope for Patients With HR-Positive, HER2-Low Metastatic Breast Cancer
Trial results from DESTINY-Breast06 indicate the effectiveness of fam-trastuzumab deruxtecan-nxki in delaying disease ...
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
(OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PDSB ...
Targeted Oncology4d
Setanaxib With Pembrolizumab Boosts Survival in Recurrent/Metastatic SCCHN
Early research suggests setanaxib combined with pembrolizumab may be a promising treatment for patients with squamous cell carcinoma of the head and neck.